BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:58 PM
 | 
Sep 21, 2012
 |  BC Extra  |  Company News

Halozyme jumps after FDA lifts hold on subcutaneous Cinryze

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $1.54 (24%) to $7.95 on Friday after it and partner ViroPharma Inc. (NASDAQ:VPHM) said FDA lifted a clinical hold on a Phase II trial of subcutaneous Cinryze in combination with Halozyme's recombinant human PH20...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >